Barinthus Biotherapeutics PLC - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BRNS Nasdaq 8731 https://www.barinthusbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Barinthus Biotherapeutics PLC

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - Apr 18th, 2024 8:10 pm
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments - Mar 20th, 2024 12:15 pm
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - Jan 5th, 2024 9:01 pm
New partnership aims to advance vaccine against MERS coronavirus - Dec 21st, 2023 12:31 pm
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD - Nov 9th, 2023 9:24 pm
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® - Nov 9th, 2023 9:01 pm
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments - Nov 9th, 2023 9:01 pm